Linzagolix (choline)

• Description :

  Linzagolix choline (KLH-2109 choline) is a non-peptide gonadotropin-releasing hormone (GnRH) antagonist with oral activity. Linzagolix choline inhibits the release of endogenous gonadotropins such as luteinizing hormone LH and follicle-stimulating hormone FSH by binding to the GnRH receptor within the pituitary gland. This inhibition results in a reduction in the production of sex hormones such as estrogen and progesterone, which in turn affects the course of sex hormone-dependent diseases. Linzagolix choline can be used in the study of sex hormone-dependent diseases such as endometriosis and uterine fibroids[1].

• Product Name Alternative :

  KLH-2109 (choline) ; OBE-2109 (choline)

• UNSPSC :

  12352005

• Target :

  GnRH Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/linzagolix-choline.html

• Smiles :

  OCC[N+](C)(C)C.O=C([O-])C1=C(C(NC2=O)=CS1)C(N2C3=CC(OCC4=C(C=CC(F)=C4F)OC)=C(C=C3F)OC)=O

• Molecular Formula :

  C27H28F3N3O8S

• Molecular Weight :

  611.59

• References & Citations :

  [1]Kobayashi K, et al. Non-clinical studies indicating lack of interactions between iron/calcium ions and linzagolix, an orally available GnRH antagonist[J]. Xenobiotica, 2022, 52 (5) : 488-497.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [1321816-57-2]